ClinicalTrials.gg
Not yet recruitingNCT07940166Updated Nov 16, 2026

A Study of HRS-8046 in Patients With Advanced Solid Tumors: Safety, Tolerability, and Pharmacokinetics

A Phase 1 interventional study of HRS-8046 Tablet in Solid Tumor, sponsored by Chengdu Suncadia Medicine Co., Ltd.. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Chengdu Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
175
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is being conducted to evaluate the efficacy and safety of HRS-8046 in patients with solid tumors, and to determine the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of HRS-8046.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Chengdu Suncadia Medicine Co., Ltd. is the lead sponsor of 24 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject has fully understood this study and voluntarily signed the form, with good compliance and willingness to participate in follow-up;
  2. Age 18-75 years, gender unrestricted;
  3. Participants with advanced solid tumors confirmed by histology/cytology;
  4. Physical Fitness Rating Performance Status 0 or 1 Part;
  5. The estimated survival time was greater than 3 months;
  6. According to 1.1 Criteria, there was at least one ;
  7. Tumor tissue samples were required for Gene Test;
  8. Participants has appropriate organ function;
  9. Women of childbearing age participants must undergo a serum pregnancy test within 7 days prior to the first medication, and the result must be negative; and must not be in the lactation period. Women of childbearing age participants and male participants whose partners were women of childbearing age must agree to comply with the requirements of high-effect from the time of signing the informed consent form until 30 days after the last dose of the drug.

Exclusion criteria

Exclusion Criteria:

  1. Prior radiotherapy within 28 days before the first dose;
  2. Treatment with any approved anti-tumor drug within 4 weeks before the first dose of the study drug;
  3. The toxicities from previous anti-tumor treatment had not recovered to Grade 1 or below;
  4. Presence of untreated or clinically unstable central nervous system (CNS) after local treatment;
  5. Use of a drug that potently/moderately inhibits or induces hepatic drug metabolizing enzyme within 14 days before the first dose;
  6. Those with severe heart disease, lung disease, infectious disease, digestive tract disease, etc.
  7. Presence of other active malignant neoplasms besides the primary tumor;
  8. Has gastrointestinal disease affecting drug administration/absorption;
  9. Participants who had undergone major surgery other than diagnosis or , or were expected to undergo major surgery during the study period;
  10. Known history of to any component of the preparation used in the trial;
  11. Other conditions deemed ineligible by the Investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
175 participants (estimated)

Study arms

  • Experimental
    HRS-8046 Group

    HRS-8046.

    Drug: HRS-8046 Tablet

Interventions

  • DrugHRS-8046 Tablet

    HRS-8046 tablet.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    Safety endpoints, assessed by number of participants with abnormal laboratory test results.

    Time frame: Approximately 2 years.

  2. Maximum tolerated dose (MTD)

    Time frame: Approximately 1 year.

  3. Recommended Phase II Dose (RP2D)

    Time frame: Approximately 2 years.

Secondary outcomes

  1. Peak concentration (Cmax)

    Pharmacokinetics (PK) parameters

    Time frame: Approximately 2 years.

  2. Time to peak concentration (Tmax)

    PK parameters

    Time frame: Approximately 2 years.

  3. Trough concentration (Ctrough)

    PK parameters

    Time frame: Approximately 2 years.

  4. Peak-to-trough fluctuation (PTF)

    PK parameters

    Time frame: Approximately 2 years.

  5. Average plasma concentration (Cavg)

    PK parameters

    Time frame: Approximately 2 years.

  6. Area under the concentration-time curve from time 0 to t (AUC0-t, where t is the time of the last measurable concentration)

    PK parameters

    Time frame: Approximately 2 years.

  7. Area under the concentration-time curve from time 0 to infinity (AUC0-inf)

    PK parameters

    Time frame: Approximately 2 years.

  8. Area under the concentration-time curve during one dosing interval (tau) at steady state (AUCtau)

    PK parameters

    Time frame: Approximately 2 years.

  9. Apparent clearance (CL/F, CLss/F)

    PK parameters

    Time frame: Approximately 2 years.

  10. Apparent volume of distribution (Vz/F, Vss/F)

    PK parameters

    Time frame: Approximately 2 years.

  11. Terminal elimination half-life (t1/2)

    PK parameters

    Time frame: Approximately 2 years.

  12. Terminal elimination rate constant (λz)

    PK parameters

    Time frame: Approximately 2 years.

  13. Accumulation ratio (Rac)

    PK parameters

    Time frame: Approximately 2 years.

  14. Objective Response Rate (ORR)

    Efficacy endpoints

    Time frame: Approximately 2 years.

  15. Duration of Response (DoR)

    Efficacy endpoints

    Time frame: Approximately 2 years.

  16. Disease Control Rate (DCR)

    Efficacy endpoints

    Time frame: Approximately 2 years.

  17. Progression-Free Survival (PFS)

    Efficacy endpoints

    Time frame: Approximately 2 years.

  18. Overall Survival (OS)

    Efficacy endpoints

    Time frame: Approximately 2 years.

07

Study locations

2 sites
  • The First Affiliated Hospital with Nanjing Medical University (Jiangsu Province Hospital)
    Nanjing, Jiangsu, China
    • Kuirong Jiang · Principal investigator
  • The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital)
    Shanghai, Shanghai Municipality 200433, China
    • Gang Jin · Principal investigator
    • Li Zhang · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jan 2029, 26 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 16, 2026
StartEst.
Nov 2026
Primary completionEst.
Jan 2029
CompletionEst.
Apr 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940166
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jan 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Zihua Wang
Contact
zihua.wang.zw368@hengrui.com
+86-518-82342973
Yan Rao
Contact
yan.rao@hengrui.com
+86-518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion